AKT1 and colorectal carcinoma: The PI3K/AKT/mTOR pathway is hyperactivated in >40% of CRC cases, and its inhibition by agents like pictilisib has shown limited clinical efficacy due to feedback activation of parallel pathways (Cancer Genome Atlas Network, 2012).